Biotechnology
Company Overview of Chemokine Therapeutics Corp.
Company Overview
1727 West Broadway
Suite 400
Vancouver, BC V6J 4S5
Canada
Founded in 1998
6 Employees
Key Executives for Chemokine Therapeutics Corp.
Chemokine Therapeutics Corp. Key Developments
An administrative law judge issued an order making findings and revoking registrations by default as to Chemokine Therapeutics Corp. The default order finds that the allegations in the order instituting proceedings are true. The company as issuer of securities registered pursuant to Section 12(g) of the Securities Exchange Act of 1934 (Exchange Act), failed to comply with Exchange Act Section 13(a) and Exchange Act Rules 13a-1 and 13a-13 by failing to file required periodic reports with the Securities and Exchange Commission (SEC). As a result, the administrative law judge ordered the revocation of the registration of each class of company’s registered securities.
In conjunction with this trading suspension, Securities and Exchange Commission (SEC or the Commission) instituted public administrative proceedings to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Chemokine Therapeutics Corp. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company is delinquent in their required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceedings.
Similar Private Companies By Industry
| Company Name | Region |
| Scimega Research, Inc. | Americas |
| Glyko Biomedical Ltd. | Americas |
| DNA LandMarks, Inc. | Americas |
| Asmacure Ltée | Americas |
| Performance Genomics Inc. | Americas |
Recent Private Companies Transactions
| Type Date |
Target | |
| No transactions available in the past 12 months. | ||

Most Searched Private Companies
| Company Name | Geographic Region |
| NYC2012, Inc. | United States |
| Bertelsmann AG | Europe |
| Lawyers Committee for Civil Rights Under Law | United States |
| Rush University | United States |
| Citizens Budget Commission | United States |
Post a JobJobs
- New York, NY | Robert W. BairdPosted: Apr 21
- Adelphi, MD | University of Maryland University CollegePosted: Jun 12
- Tarrytown, NY | Bridgeview ITPosted: Jun 16
- San Francisco, CA | Sterling Life SciencesPosted: Jun 13
Sponsored Financial Commentaries
Sponsored Links
To contact Chemokine Therapeutics Corp., please visit www.chemokine.net. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








